每日1次和每日4次白消安静脉滴注行异基因造血干细胞移植的疗效及安全性比较  

Comparison efficacy and safety of pretransplant conditioning regimens with intravenous busulfan between once-daily and every 6-hour dosing schedule in patients undergoing allogeneic stem cell transplantation

作　　者：吴远彬[1] 胡永珍[1] 李琤[1] 李慧[1] 王国征[1] 陈瑶[1] 郭坤元[1] 代喜平[1] WU Yuanbin;HU Yongzhen;LI Cheng;LI Hui;WANG Guozheng;CHEN Yao;GUO Kunyuan;DAI Xiping(Department of Hematology,Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou,510120,China)

机构地区：[1]广东省中医院血液科,广州510120

出　　处：《临床血液学杂志》2018年第4期512-516,共5页Journal of Clinical Hematology

摘　　要：目的:比较每日1次和每日4次静脉滴注含白消安预处理方案行异基因造血干细胞移植(AlloHSCT)的疗效和安全性。方法:回顾性应用白消安方案预处理行Allo-HSCT且生存期超过3个月的恶性血液病患者72例,根据给药方式分为每日1次静脉滴注组(43例)和每日4次静脉滴注组(29例),比较2组患者的3年累计生存率评估其有效性;比较2组患者的造血重建情况、移植相关并发症、移植物抗宿主病和复发情况评估其安全性。结果:2组患者的3年累计生存率差异无统计学意义;2组患者的造血重建、移植物抗宿主病发生率、复发率差异无统计学意义;2组患者的移植相关并发症比较,白消安每日1次静脉滴注组3~4级黏膜炎的发生率更高,差异有统计学意义(P<0.05),2组患者其他并发症差异无统计学意义。结论:恶性血液病的Allo-HSCT,预处理方案采用白消安每日1次静脉滴注的给药方案同每日4次给药方案具有相似疗效,但前者3~4级黏膜炎的发生率可能更高。Objective：To compare the efficacy and safety of pretransplant conditioning regimens with intravenous busulfan between once-daily and every 6-hour dosing schedule in patients undergoing allogeneic stem cell transplantation（Allo-HSCT）.Method：A total of 72 patients treated with a conditioning regimen with busulfan before Allo-HSCT was analyzed retrospectively.All patients were divided into the once-daily group（n=43）and every 6-hour group（n=29）.We evaluated the efficacy by 3 years survival rate and evaluated the safety according to the incidence of hematopoietic reconstitution,adverse events,graft-versus-host disease and relapse.Result：There was no significance difference in 3 years cumulative survival rate between the two groups.And there was no significant difference in the occurrence of graft-versus-host disease,relapse and engraftment between the two groups.Moreover,the rate of 3 to 4 degree oral mucositis in the once-daily group was higher than that in the every 6-hour group（P〈0.05）,and other toxicities had no significant difference between the 2 groups.Conclusion：The efficacy of once-daily intravenous busulfan is similar to the traditional every 6-hour intravenous busulfan.But the former possibly has the higher 3 to 4 degree oral mucositis rate.

关 键 词：白消安 预处理 异基因造血干细胞移植 

分 类 号：R733[医药卫生—肿瘤]